Clinical Trial Update: MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

A two-phase clinical trial evaluating MEK162 in combination with capecitabine in biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• MEK162 (binimetinib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Biliary Tract Cancer | Phase 1, Phase 2 | Status: COMPLETED